On the other hand, the sensitivity of ALP on diagnosis was inferior to that prostate‐specific antigen in prostate cancer 33, CA 125 in epithelial ovarian cancer 34, 35, 36, and CA 19–9 in pancreatic cancer 37, 38, 39, for which sensitivity ranged from 71.9% to 89.3%, but superior to that of CA 19–9 and CEA in colorectal cancer 40, and CA 15–3 in breast cancer 41, 42, which show sensitivity ranging from 15.4% to 31.7%. Here, CEACAM5 is linked to prostate carcinoma.